Precision transarterial chemoembolization: treatment goal and embolic endpoint

doi:10.16139/j.1007-9610.2022.02.009

Abstract

CLC Number:

R735.7

MA Jingqin, YANG Minjie, YAN Zhiping. Precision transarterial chemoembolization: treatment goal and embolic endpoint[J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 131-133.

References 21

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. doi: 10.3322/caac.21660 URL
[2]	Benson AB, D′Angelica MI, Abbott DE, et al. Hepatobi-liary cancers, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(5):541-565. doi: 10.6004/jnccn.2021.0022 URL
[3]	中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022年版)[J]. 中国实用外科杂志, 2022, 42(3):241-273.
[4]	马婧嶔, 颜志平. 肝癌介入治疗进一步思考[J]. 介入放射学杂志, 2019, 28(6):507-510.
[5]	张雯, 周永杰, 颜志平. 再论精细TACE[J]. 介入放射学杂志, 2021, 30(10):971-975.
[6]	Kudo M, Han KH, Ye SL, et al. A changing paradigm for the treatment of intermediate-stage hepatocellular carcinoma: Asia-Pacific primary liver cancer expert consensus statements[J]. Liver Cancer, 2020, 9(3):245-260. doi: 10.1159/000507370 URL
[7]	Lencioni R, de Baere T, Soulen MC, et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data[J]. Hepatology, 2016, 64(1):106-116. doi: 10.1002/hep.28453 URL
[8]	Bolondi L, Burroughs A, Dufour JF, et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions[J]. Semin Liver Dis, 2012, 32(4):348-359. doi: 10.1055/s-0032-1329906 pmid: 23397536
[9]	Piscaglia F, Ogasawara S. Patient selection for transarterial chemoembolization in hepatocellular carcinoma: importance of benefit/risk assessment[J]. Liver Cancer, 2018, 7(1):104-119. doi: 10.1159/000485471 pmid: 29662837
[10]	Chang Y, Jeong SW, Jang JY, et al. Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma[J]. Int J Mol Sci, 2020, 21(21):8165. doi: 10.3390/ijms21218165 URL
[11]	Yang K, Sung PS, You YK, et al. Pathologic complete response to chemoembolization improves survival outcomes after curative surgery for hepatocellular carcinoma: predictive factors of response[J]. HPB (Oxford), 2019, 21(12):1718-1726. doi: 10.1016/j.hpb.2019.04.017 URL
[12]	Frenette CT, Osorio RC, Stark J, et al. Conventional TACE and drug-eluting bead TACE as locoregional the-rapy before orthotopic liver transplantation: comparison of explant pathologic response[J]. Transplantation, 2014, 98(7):781-787.
[13]	Sato Y, Watanabe H, Sone M, et al. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602[J]. Ups J Med Sci, 2013, 118(1):16-22. doi: 10.3109/03009734.2012.729104 URL
[14]	Bannangkoon K, Hongsakul K, Tubtawee T, et al. Rate and predictive factors for sustained complete response after selective transarterial chemoembolization(TACE) in patients with hepatocellular carcinoma[J]. Asian Pac J Cancer Prev, 2018, 19(12):3545-3550. doi: 10.31557/APJCP.2018.19.12.3545 URL
[15]	Saito N, Tanaka T, Nishiohuku H, et al. Transarterial- chemoembolization remains an effective therapy for intermediate-stage hepatocellular carcinoma with preserved liver function[J]. Hepatol Res, 2020, 50(10):1176-1185. doi: 10.1111/hepr.13550 URL
[16]	Lencioni R, Petruzzi P, Crocetti L. Chemoembolization of hepatocellular carcinoma[J]. Semin Intervent Radiol, 2013, 30(1):3-11. doi: 10.1055/s-0033-1333648 URL
[17]	Terayama N, Matsui O, Gabata T, et al. Accumulation of iodized oil within the nonneoplastic liver adjacent to hepatocellular carcinoma via the drainage routes of the tumor after transcatheter arterial embolization[J]. Car-diovasc Intervent Radiol, 2001, 24(6):383-387.
[18]	Miyayama S. Ultraselective conventional transarterial chemoembolization: when and how?[J]. Clin Mol Hepatol, 2019, 25(4):344-353. doi: 10.3350/cmh.2019.0016 pmid: 31022779
[19]	Miyayama S, Matsui O, Yamashiro M, et al. Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil[J]. J Vasc Interv Radiol, 2007, 18(3):365-376. pmid: 17377182
[20]	Bannangkoon K, Hongsakul K, Tubtawee T, et al. Safety margin of embolized area can reduce local recurrence of hepatocellular carcinoma after superselective transarterial chemoembolization[J]. Clin Mol Hepatol, 2019, 25(1):74-85. doi: 10.3350/cmh.2018.0072 pmid: 30813680
[21]	Miyayama S, Yamashiro M, Ikeda R, et al. Efficacy of superselective conventional transarterial chemoembolization using guidance software for hepatocellular carcinoma within three lesions smaller than 3 cm[J]. Cancers (Basel), 2021, 13(24):6370. doi: 10.3390/cancers13246370 URL

Precision transarterial chemoembolization: treatment goal and embolic endpoint

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 21

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	YE Feng, GONG Xiaoyong, REN Jiajun, CAI Qiang, CHEN Sheng. Application of ERCP in diagnosis and treatment of biliary complications during perioperative period of primary liver cancer [J]. Journal of Surgery Concepts & Practice, 2023, 28(04): 355-360.
[2]	CHANG Jessica, CHEN Xuxiao, CHEN Yongjun. Role of the spleen in patients with liver cancer and cirrhosis [J]. Journal of Surgery Concepts & Practice, 2023, 28(04): 394-398.
[3]	ZHANG Hui, GONG Ling, GUO Qian, LUO Yan. Retrospective study on sugammadex for reversal of neuromuscular blockade after radiofrequency ablation of hepatic carcinoma under general anesthesia [J]. Journal of Surgery Concepts & Practice, 2023, 28(01): 72-76.
[4]	ZHANG Jixiang, XIE Zhihua, LI Wei, JIANG Xiaoqing. Classification of intrahepatic cholangiocarcinoma and hot topics in surgical treatment [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 478-482.
[5]	YIN Yanjiang, LUO Zhiwen, CHEN Xiao, ZHANG Yefan, HUANG Zhen, ZHAO Hong, ZHAO Jianjun, LI Zhiyu, ZHOU Jianguo, CAI Jianqiang, BI Xinyu. Relationship between surgical margin and prognosis of patients with intrahepatic cholangiocarcinoma [J]. Journal of Surgery Concepts & Practice, 2022, 27(03): 221-228.
[6]	CHEN Congyan, WANG Junqing, CHEN Yongjun. Gut microbiota and mechanism of liver cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(03): 256-260.
[7]	BAO Quan, XING Baocai. Surgical treatment strategy for complex bilateral multiple liver metastases of colorectal carcinoma [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 128-130.
[8]	CAO Jun, CHEN Yajin. Laparoscopic anatomic hepatectomy in treatment of hepatocellular carcinoma: standardization and think deeply [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 123-127.
[9]	FENG Hao, LÜ Zicheng, XIA Qiang. Liver transplantation in treatment of hepatocellular carcinoma: management of whole⁃process and progress in treatment [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 119-122.
[10]	HUANG Jiwei, QIU Guoteng, ZENG Yong. Advances in surgical treatment of hepatocellular carcinoma [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 113-118.
[11]	FANG Cheng, XIA Yong, WANG Kui, SHEN Feng. Conversion therapy for intrahepatic cholangiocarcinoma: status and perspectives [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 107-112.
[12]	LIU Shenyang, TANG Zhaohui, QUAN Zhiwei. Advances in surgical treatment of intrahepatic cholangiocarcinoma [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 100-106.
[13]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 93-94.
[14]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 95-99.
[15]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 134-138.